MWG Management LTD.
MWG Management Ltd. is an investment management firm registered with the SEC, filing under CIK 0001845151. The firm appears to primarily manage a concentrated portfolio of publicly-traded equities, as reported in regular 13F filings since 2021. Limited public information is available about its founding year, headquarters location, or employee count. MWG Management Ltd.'s disclosed regulatory assets under management as of the June 2025 13F-HR filing is $52 million. The firm serves institutional investors by managing a small pool of concentrated equity positions.
Investment Strategy
MWG Management Ltd. operates a concentrated equity strategy, holding a few high-conviction positions in publicly traded companies primarily in the biotechnology sector. Its 13F filings show significant allocations to companies such as Beam Therapeutics, Lyell Immunopharma, and Prime Medicine, with portfolio activity suggesting an active approach, including substantial net sales in recent quarters. The fund's focus appears to be on growth- and innovation-driven equities within healthcare and related fields.
Top Holdings
Equity Positions (3)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
B BEAM | BEAM THERAPEUTICS INC | 74.30% | $38.6M | 2,266,934 | $80.04 | $17.01 | -$5.7M |
L LYEL | LYELL IMMUNOPHARMA INC | 17.17% | $8.9M | 1,008,116 | $324.80 | $8.84 | -$1.9M |
P PRME | PRIME MEDICINE INC | 8.53% | $4.4M | 1,792,210 | $18.58 | $2.47 | +$860.3K |